Navigation Links
Study shows adverse drug events reported to the FDA have significantly increased
Date:9/10/2007

WINSTON-SALEM, N.C. A new study shows the number of drug-therapy related deaths and injuries reported to the U.S. Food and Drug Administration (FDA) nearly tripled between 1998 and 2005.

A researcher at Wake Forest University School of Medicine and colleagues reviewed serious and fatal drug events reported in that eight-year period to the FDA by consumers, health professionals and drug manufacturers, and found that serious adverse drug events increased 2.6-fold, from about 35,000 to nearly 89,000, and adverse drug-related deaths increased 2.7-fold, from about 5,500 to more than 15,000.

The study is reported in the Sept. 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

The FDA receives these reports of serious adverse drug events through its Adverse Event Reporting System. Better known to health professionals as MedWatch, this system has been in operation under the same database system since 1998, with consistent regulatory requirements for drug manufacturers.

The study also reported serious events increased four times faster than the total number of outpatient prescriptions during that period.

This marked increase of serious injuries from drug treatment is of great concern, said Curt Furberg, M.D., Ph.D., professor of public health sciences at Wake Forest University School of Medicine, and a co-author of the report. It shows current efforts to ensure the safety of drugs are not adequate, and that physicians and patients are unaware of these risks.

Furberg has previously called for far-reaching changes in drug safety regulation, including expanded authority for the FDA, higher priority for drug safety and new systems to monitor drugs once they are approved by the FDA.

The study found that a relatively small number of drugs accounted for the most reported serious adverse drug events, said Thomas J. Moore, A.B., of the Institute for Safe Medication Practices (ISMP), and the lead author.

The authors of this study took into account several factors that might influence their findings.

We saw no evidence that doctors and patients had become more active in reporting events in some across-the-board fashion, said Furberg. We also tried to eliminate noise in the reporting system, by excluding reports from more than 14 days after a drug was withdrawn. In addition, we excluded events that were not serious, and foreign reports to focus on U.S. risks.


'/>"/>

Contact: Shannon Koontz
shkoontz@wfubmc.edu
336-716-2415
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... ... announced that it has been honored as one of the nation’s most accomplished ... InformationWeek Elite 100. Horizon received the recognition for technology achievements that have enabled ...
(Date:5/3/2016)... ... May 03, 2016 , ... BioPlus Specialty Pharmacy ... at the 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 at the ... health care conference for the specialty pharmacy industry, with thousands of pharmacy providers, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean Benefit Solutions, Inc., the ... service center in La Vergne, Tennessee, near Nashville. The new center will complement ... Empyrean client services. , “Our Nashville-area center allows us to achieve several goals,” ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... one of Canada’s top Information and Communication Technology (ICT) companies in the annual ... Multinational ICT companies operating in Canada, as ranked by revenue. , “We ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
Breaking Medicine Technology: